Effects of the levels of astaxanthin in the diet on the flesh pigmentation of Rainbow trout

A feeding trial was conducted to study the effects of dietary astaxanthin concentration on muscle pigmentation of rainbow trout ( Oncorhynchus mykiss) with a mean initial weight of 270 g fed diets supplemented with astaxanthin in diet concentrations of 60 (group II) and 90 mg/kg (group III) for 35 days. A control (I) group received a diet without astaxanthin. At the end of the experiment, the trout showed average body weight increases of 250.660g, 261.675 g and 234.410 g, and the flesh reached a level of 0.695 mg/kg, 10.539 mg/kg and 11.954 mg carotenoid/kg in groups I, II and III, respectively (initially, 0.595 mg/kg). Fish pigmentation increased with increasing dietary carotenoid concentration. But the retention coefficients decreased as the pigment dose in the diet increased. Key Words : Rainbow trout ( Oncorhynchus mykiss), pigmentation, astaxanthi

Effect of natural and synthetic carotenoid sourced on pigmentation of rainbow trouth (Oncorhynchus mykiss)

A feeding trial was conducted to assess the effects of supplementing the diets of commercial-size rainbow trout (Oncorhynchus mykiss) with red pepper as a natural carotenoid source and synthetic astaxanthin. Diets without carotenoid supplemented (control) and containing 3% or 6% red pepper and 0.05% "Carophyll Pink 8%" were given to groups 1-4, respectively. Rainbow trout, with weight of groups between 470 and 483 g, were fed four different diets for 45 days. At the end of the experiment, the trout showed an average body weight increase of 157.599 g, 110.729 g, 136.641 g and 190.091 g, and feed conversion averaged 2.464, 3.175, 2.661 and 2.055 for groups 1-4, respectively. Steak and fillet color card scores were 0.000 and 10.000 for group I, 0.350 and 10.460 for group 2, 0.580 and 10.865 for group 3, 3.260 and 13.620 for group 4. The flesh reached a level of 0.526, 1.099, 1.457 and 5.568 mg carotenoid/kg for groups 1-4, respectively (initial mean carotenoid concentration of 0.559 mg/kg). Synthetic astaxanthin resulted in significantly higher levels of total carotenoid in the flesh than the red pepper pigment. Red pepper pigment resulted in small, but statistically significant deposits compared with the control group (P<0.05). The carotenoid retention in the flesh was 2% for red pepper groups and 12% for the synthetic astaxanthin group

COVID-19 Pneumonia After SARS-CoV-2 Vaccination with CoronaVac: A Case Series from Turkey.

Coronavirus disease 2019 is a novel viral infection that has caused a pandemic globally. Many kinds of vaccine development studies were conducted to prevent the spread and deaths. The CoronaVac is the most commonly used vaccine in Turkey. Phase 3 trials from various countries revealed that CoronaVac efficacy ranged from 50.7% to 91.25% but increased in moderate or severe cases to 100%. Additionally, it was remarkable owing to high seroconversion rates achieving up to 100%. After the vaccine campaign began in Turkey, critically ill patients continued to admit to our center's intensive care unit though they had been vaccinated with 2 doses of CoronaVac. The clinical course of these patients revealed that they are still at high risk of severe disease and death. Therefore, we aimed to share these patients' clinical characteristics and disease course, laboratory, and radiologic data

Clinical and molecular evaluation of MEFV gene variants in the Turkish population: a study by the National Genetics Consortium

Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disorder with recurrent fever, abdominal pain, serositis, articular manifestations, erysipelas-like erythema, and renal complications as its main features. Caused by the mutations in the MEditerranean FeVer (MEFV) gene, it mainly affects people of Mediterranean descent with a higher incidence in the Turkish, Jewish, Arabic, and Armenian populations. As our understanding of FMF improves, it becomes clearer that we are facing with a more complex picture of FMF with respect to its pathogenesis, penetrance, variant type (gain-of-function vs. loss-of-function), and inheritance. In this study, MEFV gene analysis results and clinical findings of 27,504 patients from 35 universities and institutions in Turkey and Northern Cyprus are combined in an effort to provide a better insight into the genotype-phenotype correlation and how a specific variant contributes to certain clinical findings in FMF patients. Our results may help better understand this complex disease and how the genotype may sometimes contribute to phenotype. Unlike many studies in the literature, our study investigated a broader symptomatic spectrum and the relationship between the genotype and phenotype data. In this sense, we aimed to guide all clinicians and academicians who work in this field to better establish a comprehensive data set for the patients. One of the biggest messages of our study is that lack of uniformity in some clinical and demographic data of participants may become an obstacle in approaching FMF patients and understanding this complex disease